Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
Monday June 2, 5:10 pm ET
SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced that it will host a conference call with simultaneous webcast to discuss the preliminary results of its Phase 2 clinical study of R788, a novel, oral Syk kinase inhibitor, in patients with B-cell non-Hodgkin's lymphomas on Tuesday, June 3, 2008 at 8:00 a.m. EDT. Participating on the call will be Rigel senior management and the principal investigator on the study, Jonathan Friedberg, M.D., M.S.Sc., Associate Professor of Medicine, James P. Wilmot Cancer Center, University of Rochester Medical Center.
ADVERTISEMENT
Conference Call and Webcast Information
To access the live call, please dial 866-356-3095 (domestic) or 617-597-5391 (international) 10 minutes prior to the start time and use the passcode 61157501. A replay of the call will be available, in webcast and podcast formats, at approximately 10:00 a.m. EDT on June 3, 2008 until June 10, 2008. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 11043962. The conference call will also be webcast live and can be accessed from Rigel's website at rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.
Further information on R788 in B-cell lymphoma is available at Rigel's website: rigel.com. |
